4.0 Article

Prevalence, Persistence, and Sociodemographic Correlates of DSM-IV Disorders in the National Comorbidity Survey Replication Adolescent Supplement

Journal

ARCHIVES OF GENERAL PSYCHIATRY
Volume 69, Issue 4, Pages 372-380

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/archgenpsychiatry.2011.160

Keywords

-

Categories

Funding

  1. Analysis Group
  2. Bristol-Myers Squibb
  3. Eli Lilly and Co
  4. EPI-Q
  5. GlaxoSmithKline
  6. Johnson & Johnson Pharmaceuticals
  7. Ortho-McNeil Janssen Scientific Affairs
  8. Pfizer Inc
  9. sanofi-aventis
  10. Shire US Inc.
  11. National Institute of Mental Health [U01-MH60220, R01-MH66627, U01MH060220-09S1, R01-MH070884, R13-MH066849, R01-MH069864, R01-MH077883]
  12. Robert Wood Johnson Foundation [044780]
  13. John W. Alden Trust
  14. National Institute on Drug Abuse
  15. Fogarty International Center of the National Institutes of Health [FIRCA R03-TW006481]
  16. John D. and Catherine T. MacArthur Foundation
  17. Pfizer Foundation
  18. Pan American Health Organization
  19. AstraZeneca
  20. Ortho-McNeil
  21. Pfizer
  22. Wyeth

Ask authors/readers for more resources

Context: Community epidemiological data on the prevalence and correlates of adolescent mental disorders are needed for policy planning purposes. Only limited data of this sort are available. Objective: To present estimates of 12-month and 30-day prevalence, persistence (12-month prevalence among lifetime cases and 30-day prevalence among 12-month cases), and sociodemographic correlates of commonly occurring DSM-IV disorders among adolescents in the National Comorbidity Survey Replication Adolescent Supplement. Design: The National Comorbidity Survey Replication Adolescent Supplement is a US national survey of DSM-IV anxiety, mood, behavior, and substance disorders among US adolescents based on face-to-face interviews in the homes of respondents with supplemental parent questionnaires. Setting: Dual-frame household and school samples of US adolescents. Participants: A total of 10 148 adolescents aged 13 to 17 years (interviews) and 1 parent of each adolescent (questionnaires). Main Outcome Measures: The DSM-IV disorders assessed with the World Health Organization Composite International Diagnostic Interview and validated with blinded clinical interviews based on the Schedule for Affective Disorders and Schizophrenia for School-Age Children. Good concordance (area under the receiver operating characteristic curve >= 0.80) was found between Composite International Diagnostic Interview and Schedule for Affective Disorders and Schizophrenia for School-Age Children diagnoses. Results: The prevalence estimates of any DSM-IV disorder are 40.3% at 12 months (79.5% of lifetime cases) and 23.4% at 30 days (57.9% of 12-month cases). Anxiety disorders are the most common class of disorders, followed by behavior, mood, and substance disorders. Although relative disorder prevalence is quite stable over time, 30-day to 12-month prevalence ratios are higher for anxiety and behavior disorders than mood or substance disorders, suggesting that the former are more chronic than the latter. The 30-day to 12-month prevalence ratios are generally lower than the 12-month to lifetime ratios, suggesting that disorder persistence is due more to episode recurrence than to chronicity. Sociodemographic correlates are largely consistent with previous studies. Conclusions: Among US adolescents, DSM-IV disorders are highly prevalent and persistent. Persistence is higher for adolescents than among adults and appears to be due more to recurrence than chronicity of child-adolescent onset disorders.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available